ARWR — Arrowhead Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.77bn
- $2.56bn
- $240.74m
Annual income statement for Arrowhead Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 169 | 88 | 138 | 243 | 241 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 108 | 181 | 287 | 422 | 446 |
| Operating Profit | 61.2 | -93.2 | -149 | -179 | -205 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 68.1 | -84.6 | -141 | -173 | -206 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 68 | -84.6 | -141 | -176 | -209 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 68 | -84.6 | -141 | -176 | -205 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 68 | -84.6 | -141 | -176 | -205 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.689 | -0.839 | -1.36 | -1.67 | -1.92 |